Frontpage Hero

Because we care, we need to act

Statement from the CEO

Building for balance and growth

"Sobi is delivering on a solid strategy for growth. Building on our strength in Haemophilia, we aim to grow the business with a broader Specialty Care portfolio to ensure long-term sustainability and strength and make a real diffrence for people with rare diseases".

Press releases

Post-hoc longitudinal analysis from B-LONG and B-YOND studies shows patients who progressed to individualised prophylactic dosing intervals of 14 days or longer maintained low annualised bleeding rates.

Swedish Orphan Biovitrum AB (publ) (Sobi™)(STO:SOBI) and Bioverativ Inc. (NASDAQ: BIVVV) today an...

12/11/2017 - 16:02

Swedish Orphan Biovitrum AB (publ) (Sobi™)(STO:SOBI) and Bioverativ Inc. (NASDAQ: BIVV) today announce the results of a new, post-hoc, longitudinal analysis of the pivotal Phase 3 A-LONG study and ASPIRE long-term extension study, showing that weekly prophylactic dosing with its extended half-life t...

12/10/2017 - 15:02

Swedish Orphan Biovitrum AB (publ) (Sobi™) has received approval from Health Canada for an oral suspension formulation of Orfadin® (nitisinone). Orfadin is a medicine approved in multiple countries across North America and Europe for use in combination with dietary restriction of tyrosine and phenyl...

11/27/2017 - 14:00

Swedish Orphan Biovitrum AB (publ) (Sobi™) announces that the first patient has been randomised in the phase 3 study anaSTILLs, to evaluate efficacy and safety of anakinra in the treatment of Still’s disease.

The purpose of the study is to assess the efficacy and to evaluate the safety of anakinra i...

11/16/2017 - 09:00
Contact us

Sobi Head Office

info@sobi.com
+46 8 697 20 00
Tomtebodavägen 23A
SE-112 76 Stockholm, Sweden